Burning Mouth Syndrome Management

Diagnostic Considerations

• Burning mouth syndrome is characterized by a burning sensation of the oral mucosa without clinically apparent mucosal alterations, commonly affecting the tongue tip, lateral borders, lips, palate, and buccal mucosa, primarily in peri- and post-menopausal women 1, 2
• The diagnostic process requires exclusion of secondary causes, including local factors such as oral candidiasis and mucosal lesions, systemic factors like hematological and auto-immune disorders, pharmacological side effects, and other conditions 1

Clinical Presentation and Management

• Burning mouth syndrome may be accompanied by dry mouth, abnormal taste, depression, and poor quality of life, with pain severity ranging from mild to severe 2
• The American College of Physicians recommends a multidisciplinary approach for managing BMS, including reassurance, education, cognitive behavioral therapy, and neuropathic pain medications, with gabapentin being a first-line pharmacological option showing efficacy in reducing burning sensation in 50% of patients 3
• The British Journal of Anaesthesia suggests that cognitive behavioral therapy is a primary intervention for BMS, helping address psychological components that may contribute to or exacerbate symptoms 1, 2

Pharmacological Management

• Gabapentin has demonstrated efficacy in randomized controlled trials, with 50% of patients experiencing reduction in burning sensation 3
• Amitriptyline has shown some benefit in open-label studies for managing BMS symptoms 2
• Topical treatments, including high-potency topical steroids and viscous lidocaine, may provide temporary relief for BMS symptoms 3

Management of Associated Symptoms

• For dry mouth, improving hydration, limiting caffeine intake, using saliva substitutes, and moisture-preserving mouth rinses/sprays may help alleviate mild symptoms 3
• Systemic sialagogues, such as cevimeline or pilocarpine, may be considered for moderate to severe dry mouth symptoms 3, 4
• Avoiding crunchy, spicy, acidic, or hot food and drinks that may exacerbate discomfort is recommended 3

Special Considerations

• Treatment failures are common in BMS management, with a high percentage of failures 1
• Inadequate reassurance, failing to emphasize that the condition won't worsen, is crucial for patient anxiety and should be avoided 1

Burning Mouth Syndrome Management

Clinical Presentation and Diagnosis

• The British Journal of Anaesthesia reports that burning mouth syndrome is characterized by a burning sensation in the oral mucosa, typically affecting the tongue, lips, palate, and buccal mucosa, with pain severity ranging from mild to moderate, and often accompanied by dry mouth, abnormal taste, depression, and poor quality of life, in patients with autoimmune disorders, and medication side effects 5
• Autoimmune disorders, such as those reported by the British Journal of Anaesthesia, should be excluded as a potential cause of burning mouth syndrome, as they can contribute to symptoms 5

Management

Pharmacological Management

• The British Journal of Anaesthesia suggests that alpha lipoic acid combined with gabapentin has demonstrated good outcomes in reducing burning sensation in patients with burning mouth syndrome 5
• Topical treatments, including clonazepam, diazepam, and capsaicin, as reported by the British Journal of Anaesthesia, have shown some effect in managing symptoms of burning mouth syndrome 5

Burning Mouth Syndrome Management

Diagnostic Considerations

• Burning mouth syndrome is characterized by burning sensations of the oral mucosa without clinically apparent mucosal alterations, commonly affecting the tongue tip, lateral borders, lips, palate, and buccal mucosa, primarily affecting peri- and post-menopausal women 6

Non-Pharmacological Approaches

• Cognitive behavioral therapy is recommended as a primary intervention to address psychological components that may contribute to or exacerbate symptoms 6

Management of Associated Symptoms

• For taste disturbances, regular oral hygiene with bland rinses (salt and sodium bicarbonate solution) is recommended 7
• Avoid irritating oral care products containing alcohol or strong flavoring agents 7

Treatment Algorithm

• If inadequate response after 4-6 weeks, consider referral to pain specialist or neurologist 6
• For refractory cases, evaluate for comorbid depression or anxiety and treat appropriately, and consider combination therapy with multiple agents 7

Important Considerations

• Treatment failures are common in BMS management, and patients should be informed about the chronic nature of the condition 6
• Avoid irritating oral care products containing alcohol or strong flavoring agents 7

Burning Mouth Syndrome Treatment

Introduction to Burning Mouth Syndrome Management

• The British Journal of Anaesthesia recommends referring patients for cognitive behavioral therapy to address psychological components that contribute to or exacerbate symptoms, and also suggests excluding systemic factors such as hematological disorders and autoimmune conditions before treating as primary BMS 8
• Combination approaches, such as CBT plus pharmacotherapy, generally outperform monotherapy, according to the British Journal of Anaesthesia 8

Pharmacological Treatment Options

• Alpha lipoic acid combined with gabapentin shows good outcomes, outperforming monotherapy in available trials, as reported by the British Journal of Anaesthesia 8
• The British Journal of Anaesthesia suggests considering amitriptyline when gabapentin is ineffective or not tolerated 8

Management of Burning Mouth Syndrome

Initial Therapeutic Approach

• For a post-menopausal woman with burning mouth syndrome (BMS), the initial approach should prioritize excluding secondary causes through specific laboratory tests, followed by reassuring the patient that the condition will not worsen, and then starting cognitive-behavioral therapy as the primary intervention, with gabapentin as a first-line pharmacological option if necessary, as recommended by the British Journal of Anaesthesia 9

Diagnostic Evaluation

• A complete blood count with formula is essential to identify hematological disorders, as suggested by the British Journal of Anaesthesia 9
• An oral mucosa examination is crucial to exclude oral candidosis, mucosal lesions, or other visible pathologies, according to the British Journal of Anaesthesia 9
• Oral swabs should be taken if a fungal or bacterial infection is suspected, as recommended by the British Journal of Anaesthesia 9

Primary BMS Management

• Reassurance that the condition will not worsen is crucial and often represents a fundamental therapeutic element, as stated by the British Journal of Anaesthesia 9
• Cognitive-behavioral therapy (CBT) is recommended as the primary intervention for primary BMS, as it addresses the psychological components that contribute to or exacerbate symptoms, according to the British Journal of Anaesthesia 9
• Gabapentin is a first-line pharmacological option, with a demonstrated efficacy in reducing burning sensation in 50% of patients in randomized controlled trials, as reported by the British Journal of Anaesthesia 9

Symptomatic Management

• The combination of alpha-lipoic acid with gabapentin 300 mg has shown the best results compared to monotherapy, as suggested by the British Journal of Anaesthesia 9
• Topical treatments (clonazepam, diazepam, capsaicin) have shown some effect in managing symptoms, according to the British Journal of Anaesthesia 9

Therapeutic Escalation Algorithm

• Weeks 0-2: Reassurance + CBT + management of associated symptoms, as recommended by the British Journal of Anaesthesia 9
• Weeks 2-6: If inadequate response, add gabapentin 300 mg, as suggested by the British Journal of Anaesthesia 9
• Weeks 6-10: If partial response, consider combination with alpha-lipoic acid, according to the British Journal of Anaesthesia 9

Prognostic Considerations

• The prognosis is generally unfavorable, with only a small number of patients achieving complete resolution, as stated by the British Journal of Anaesthesia 9

Guidelines on Apremilast Use and Symptomatic Management in Burning Mouth Syndrome

1. Apremilast – Indications, Mechanism, and Safety

• Apremilast is FDA‑approved for psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; it has no approved indication for burning mouth syndrome. (American Academy of Dermatology data) 10
• The drug acts by inhibiting phosphodiesterase‑4, thereby down‑regulating Th1, Th17 and type‑1 interferon inflammatory pathways—mechanisms that are not involved in the neuropathic pathophysiology of burning mouth syndrome. (American Academy of Dermatology) 10
• The most frequent adverse effects are diarrhea, nausea, upper‑respiratory‑tract infections, and headache, with 70‑80 % of gastrointestinal events occurring within the first two weeks of treatment. (American Academy of Dermatology) 10
• Depression occurs in roughly 1 % of patients receiving apremilast, requiring routine monitoring. (American Academy of Dermatology) 10
• Clinically significant weight loss (> 5 % of baseline body weight) is reported in about 12 % of treated individuals and may necessitate drug discontinuation. (American Academy of Dermatology) 10

2. Topical and Supportive Therapies for Burning Mouth Syndrome

• High‑potency topical corticosteroids and viscous lidocaine preparations can provide temporary symptomatic relief of oral burning sensations. (National Comprehensive Cancer Network guidelines) 11
• Management of xerostomia includes encouraging adequate hydration, limiting caffeine intake, and using saliva substitutes or moisture‑preserving oral rinses. (National Comprehensive Cancer Network guidelines) 11
• Dietary recommendations advise avoidance of crunchy, spicy, acidic, or hot foods that may aggravate oral discomfort. (National Comprehensive Cancer Network guidelines) 11